x
CME-Tagline

Making the Right Moves for the Long-Term Management of Antipsychotic-Induced TD: Evidence-Based Strategies to Improve Quality of Life and Patient-Centered Outcomes

CMEO Podcast

Premiere Date: Tuesday, March 22, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Wednesday, March 22, 2023

Faculty


Christoph U. Correll, MD Christoph U. Correll, MD (Moderator)
Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Investigator, Center for Psychiatric Neuroscience
Feinstein Institute for Medical Research
Manhasset, NY
The Zucker Hillside Hospital, Department of Psychiatry
Glen Oaks, NY

Joohi Jimenez-Shahed, MD Joohi Jimenez-Shahed, MD 
Medical Director, Movement Disorders Neuromodulation & Brain Circuit Therapeutics
Associate Professor, Neurology and Neurosurgery
Icahn School of Medicine at Mount Sinai
New York, NY

Statement of Need

TD is a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotic medications. Two vesicular monoamine transporter 2 (VMAT2) inhibitors are approved by the U.S. Food and Drug Administration (FDA) for the treatment of TD, with the American Psychiatric Association (APA) and American Academy of Neurology (AAN) endorsing them as first-line therapy for TD. Despite evidence supporting the use of VMAT2 inhibitors, incorporating VMAT2 inhibitors into clinical practice may be a challenge, particularly in terms of identifying optimal dosing strategies to achieve significant reductions in Abnormal Involuntary Movement Scale (AIMS) scores.

Join Drs. Correll and Jimenez-Shahed as they discuss the pathogenesis of TD and analyze the latest clinical evidence on the role of VMAT2 inhibitors in reducing the burden of TD and improving QoL and restoration of function in patients with TD.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Incorporate evidence-based, expert guidance on the use of VMAT2 inhibitors to minimize the burden and improve QoL in patients with TD.

Financial Support

Supported by an educational grant from Teva Pharmaceuticals.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists who specialize in psychiatry and/or neurology

Credit Information


ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Correll reports the following financial relationships:

Consultant: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Alkermes; Allergan; Angelini Pharma Inc; Axsome Therapeutics, Inc.; Cardio Diagnostics Inc.; Gedeon Richter; Holmusk; Intra-Cellular Therapies, Inc; Janssen Pharmaceuticals, Inc.; Karuna Therapeutics; LB Pharmaceuticals; Lundbeck; MedAvante-ProPhase Inc; MedinCell; Medscape; Merck & Co., Inc.; Mindpax; Mylan; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc; Otsuka America Pharmaceutical, Inc; Pfizer Inc; Pharmabrain GmbH; Recordati; Relmada Therapeutics, Inc.; Rovi; Seqirus UK Limited; Servier Laboratories; SK Life Science, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Teva Pharmaceuticals USA, Inc.; and Viatris Inc.

Grants: Janssen Pharmaceuticals, Inc. and Takeda Pharmaceutical Company

Royalties: UpToDate

Speaker/Advisory Board: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Alkermes; Allergan; Angelini Pharma Inc; Aristo Pharma; Axsome Therapeutics, Inc.; Damitsa; Gedeon Richter; Hikma Pharmaceuticals; IntraCellular Therapies, Inc.; Janssen Pharmaceuticals, Inc.; Karuna Therapeutics; LB Pharmaceuticals; Lundbeck; MedAvante-ProPhase Inc; MedinCell; Merck & Co., Inc.; Mitsubishi Tanabe Pharma; Mylan; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc; Otsuka America Pharmaceutical, Inc; Recordati; Rovi; Seqirus UK Limited; Servier Laboratories; SK Life Science, Inc.; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Teva Pharmaceuticals USA, Inc.; and Viatris Inc.

Stock Options: Cardio Diagnostics Inc.; Mindpax; and LB Pharmaceuticals

Dr. Jimenez-Shahed reports the following financial relationships:

Advisory Board: BlueRock Therapeutics (DSMC)

Consultant: AbbVie Inc.; Medtronic; Revance; Signant Health; Spark Therapeutics, Inc.; St. Jude Medical; and Teva Pharmaceuticals USA, Inc.

Research Support: Michael J. Fox Foundation and Impax Laboratories

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Marlon (Tony) Graham, MD (peer reviewer)
  • Kashemi D. Rorie, PhD (planning committee)
  • Evan Luberger (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    This document was last modified on:

    PD-080-032222-15